Since its foundation in 1989, Medis has been deeply involved in X-ray imaging, particularly 2D and 3D QCA (Quantitative Coronary Angiography), with solutions used worldwide, particularly in Japan. Given the increasing clinical interest in coronary physiology globally, the Medis’ Applied Research team in Leiden, the Netherlands, began exploring a new solution in 2013.
Read MoreIn this July edition of the Medis QFR blog article we are sharing five publications with you.
Read MoreIn this June edition of the Medis QFR blog article we are sharing five publications with you.
Read MoreToday, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).
Read MoreWe are excited to officially announce the launch of Medis QFR® 3.0, our latest solution designed to streamline your Cath lab workflow for physiology and morphology assessments of intermediate coronary lesions. This new version will bring innovative features, accessibility from anywhere within the hospital network, and a completely new look & feel.
Read MoreMedis recently sponsored a hands-on session featuring Medis Suite MR as part of the Mexican Society of Echocardiography and Cardiovascular Imaging’s 3-day course (2-4 May).
Read MoreClinical experts will share their experiences with Medis QFR® 3.0 through a combination of presentations and hands-on sessions, and you could interact with them in a friendly and open environment. Be ready to learn how they successfully implemented Medis QFR®, to reach the expected clinical outcomes for better patient care.
Read More– Learn how the newest QFR technology enables coronary physiology analysis in under 30 seconds.
– Understand the role of QFR-IMR as a diagnostic tool for coronary microvascular dysfunction assessment.
– Learn how QFR paves the way for new horizons in treatment options.
